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Intravenous Pentoxifylline for the Treatment of Chronic Critical 
Limb Ischaemia 
The European Study Group 
The European Study Group comprises the following: Belgium: P. Van den Brande, D. Munck, J. Wautrechts 
(Brussels), J. De Roose (Gent), P. Depuydt (Ostend); Denmark: S.J. Joergensen (Hillerod); Germany: K.-H. Labs 
(Wiesbaden); Great Britain: M. Gough (Bradford), J.M.D. Galloway (Hull), R.C. Kester (Leeds), P. Wake 
(Warrington), S.H. Leveson (York); Ireland: M.P. Colgan, D. Moore, G. Shanik (Dublin); The Netherlands: B. 
Knippenberg, S. Gravenhage; Sweden: P. Ortenwall, B. Risberg (G6teborg), P.Konrad, A. Molde (Kalmar), B. 
Lnndqvist, L. Spangen (Karlstad), G. Emtersj6, M.B. Thomsen (Kristianstad), D. Bergqvist, A. Lundell 
(Malm6), K.-A. Angqvist, B. Hedberg (Ume~), H. Bj6rkrnan, P. Weber (V~ixj6). 
Independent consultants: Pain measurement: H.J. McQuay (Oxford); Radiological assessment: M.W.G. Wren 
(Portsmouth); Surgical assessment: G. Prout (Portsmouth). 
Objectives: To investigate the safety and efficacy of intravenous pentoxifylline infusion therapy, 600 mg twice daily for up 
to 21 days, for the management ofpatients with chronic critical limb ischaemia (CLI). 
Design: A prospective, randomised, ouble-blind, placebo-controlled, parallel-group, multicentre trial. 
Setting: County and university hospitals in six European countries. 
Materials: A total of 314 patients uffering from CLI were enrolled: 157 patients were allocated to each treatment. 
Outcome measures: Patients were reviewed after 7 days of treatment and continued in the study for up to a further 14 
days if their condition had not deteriorated. Rest pain (assessed by pain score and visual analogue scale), sleep disturbances 
and analgesic onsumption were measured. 
Results: Both intention-to-treat nd per protocol analyses howed significantly positive results in favour of pentoxifylline 
over placebo. Severity of rest pain was consistently and significantly lower as shown by the results of the pre-infusion pain 
scores (p = 0.007), pain visual analogue scales (p < 0.001) and scores describing rest pain-related sleep disturbances 
(p = 0.003). Treatment response was not influenced by the presence of diabetes mellitus or by eligibility for surgery. 
Conclusion: These results justify the use of intravenous pentoxifylline infusion therapy for the management'of rest pain 
in patients with CLI. 
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Introduction 
Chronic critical imb ischaemia (CLI) is an advanced 
stage of severe peripheral vascular disease (PVD), 
with a significant morbidity and mortality. The condi- 
tion is characterised by persistent rest pain, requiring 
regular analgesia, and/or ulceration or gangrene of 
the foot or toes. It may represent the end-stage of 
progressive deterioration of intermittent ctaudica- 
tion. ~'2 However a considerable number of patients 
develop critical ischaemia without previous claudica- 
tion. The prevalence of CLI is not known exactly but 
from the numbers of amputations it can be concluded 
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that it constitutes a significant clinical problem. 
Figures given in the literature for the deterioration rate 
from intermittent claudication to severe ischaemia 
vary widely depending on the anatomical distribution 
of atherosclerotic lesions, the pattern of risk factors, 
the severity of claudication and other prognostic 
factors z-6. An estimate of 10-20% may be a con- 
servative but acceptable proportion of patients who 
progress from intermittent claudication to CLI. Dia- 
betics have a particularly poor prognosis, with an 
estimated five-fold increase in risk of deterioration. 6 
Current treatment options are generally surgical 
apart from approaches such as epidural spinal cord 
electrical stimulation, lumbar chemical sympathect- 
omy and percutaneous transluminal angioplasty 
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(PTA). Approximately 60% of patients undergo vas- 
cular reconstruction, often as surgical emergencies; 
20% undergo primary amputation and 20% some 
other form of temporary treatment. 6 Given the high 
prevalence of concurrent diseases and other manifes- 
tations of atherosclerosis, particularly coronary heart 
disease and extracranial cerebral vascular disease in 
this patient group, 7-1° the above-mentioned proce- 
dures are associated with a significant perioperative 
morbidity and mortality and a poor long-term prog- 
nosis. ~ As many patients are not eligible for surgery, 
pharmacotherapy remains one of the alternative meth- 
ods of treatment. 
An internationally accepted gold standard for the 
conservative management of CLI has not yet been 
established. Since CLI patients suffer from abnor- 
malities in the macro- and microcirculation, 12'13 ele- 
vated fibrinogen levels ~4 and impaired leucocyte 
function, 15 the use of vasoactive agents has been a 
rational approach to conservative management. 
Numerous studies have investigated the efficacy of 
vasoactive agents in the treatment of CLI. However, a 
lack of standardisation in the definition of CLI, 
varying patient populations, lack of a suitable stan- 
dard for comparison and the use of different efficacy 
outcome measures have prevented extrapolation of 
any positive findings to the general clinical situation. 
Clinical trial methodology has recently been discussed 
in the European Consensus Document on Critical Leg 
Ischaemia. ° As persistently recurring rest pain is the 
main symptom, the primary outcome of any trial 
should be pain reduction that is independent of any 
analgesic effect of the test medication itself. This 
reduction in rest pain is important regardless of 
whether an invasive treatment program follows. 
Pentoxifylline, a vasoactive substance with hae- 
morheological properties, is effective in the treatment 
of PVD. 16-21 Several open studies have suggested that 
intravenously administered pentoxifylline may also be 
effective in the acute management of more severe 
stages of PVD, including CLI. 2z-28 On the basis of 
these preliminary findings, this multicentre, rando- 
raised, double-blind, placebo-controlled study was 
undertaken to evaluate the efficacy of pentoxifylline in 
the relief of ischaemic rest pain and acute manage- 
ment of patients with chronic CLI. Treatment effects 
on walking capacity were also investigated. 
Patients and Methods 
The aim of this randomised, double-blind, placebo- 
controlled, parallel-group multicentre study was to 
investigate the efficacy of intravenous pentoxifylline 
(Trental®, Hoechst AG, Germany) infusion therapy, 
600 mg twice-dail~ for the treatment of rest pain due 
to CLI in patients with severe PVD. Treatment effects 
on walking capacity were also assessed. 
A total of 18 hospital centres in Belgium, Den- 
mark, Great Britain, Ireland, The Netherlands and 
Sweden participated. The study was approved by the 
relevant hospital ethics committees and conducted in 
accordance with the Declaration of Helsinki, Venice 
Revision, 1983. All patients gave their informed 
consent before entering the trial. 
Patients 
Patients who were older than 50 years and hospi- 
talized with persistent, severe rest pain due to CLI, 
and with clinical evidence of severe PVD, were 
provisionally enrolled in the study. The definition of 
CLI was based on the proposal of the Working Party of 
the International Vascular Symposium (1982), 29 which 
was the most recent proposal for a standardised 
definition of CLI when the study was started: i.e. 
persistent and severe rest pain, sleep disturbances and 
the need for repeated analgesia for pain relief, present 
for at least 3 weeks. The presence of PVD was 
confirmed by vascular examination, haemodynamic 
assessment and angiography. All patients suffered 
from PVD Fontaine stages III/IV 3° and hence had a 
limited walking capacity (pain-free claudication dis- 
tance less than 50 m). Previous treatment with 
antiplatelet and/or vasoactive drugs was discon- 
tinued, and cardiovascular drug therapy was stabi- 
lised on study entry. During the trial, analgesic 
therapy was limited to paracetamol, paracetamol/ 
dextropropoxyphene, morphine sulphate or pethidine 
on demand. 
Patients with evidence of any of the following 
conditions were excluded: Buerger's disease, immu- 
nological arteritis, renal or hepatic failure, uncompen- 
sated heart failure, severe circulatory or metabolic 
diseases, major infection, acute embolism or thrombo- 
sis, active neoplastic disease or malignant disease 
treated with immunosuppressive or cytotoxic drugs in 
the last 12 months, myocardial infarction or unstable 
angina pectoris within the last 3 months, major 
surgery within the last 4 weeks, xanthine hyper- 
sensitivity, abnormal clotting screen, alcoholism or 
drug addiction. Patients who had received a ther- 
apeutic agent with a well-defined potential for major 
organ toxicity within the last 3 months, or who 
required intravenous infusion of more than 1000ml 
per 24 h, in addition to the study drug vehicle, were 
also excluded. 
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Study Design 
Patients were treated for up to 21 days. At baseline, all 
patients underwent a comprehensive screening proce- 
dure, including angiograph3~ determination f periph- 
eral haemodynamics, general physical and vascular 
examinations, pain and walking assessments, chest 
X-ray, 12-lead ECG, and routine safety laboratory 
investigations. During the first 7 days of the study, 
treatment effects and the patient's suitability for 
surgery were evaluated. Patients whose condition had 
stabilised at the end of 7 days (improvement or no 
change in pain intensity and/or sleep disturbance 
questionnaire scores) continued in the study for a 
further 14 days. Pain assessments and analgesic 
consumption were recorded aily. Walking capacity 
assessments and general physical and vascular exam- 
inations were conducted at the end of each week of 
treatment. 
Adverse events were obtained by spontaneous 
reporting. Wherever possible, information on the 
onset, duration, severity and possible causality (in 
relation to the study drug) of the event was provided. 
Details of all withdrawals and of surgery performed 
within 21 days of commencing the study were also 
noted. Routine laboratory safety investigations, chest 
X-ray and ECG were repeated at the final visit. 
Treatment 
Patients were randomised consecutively to receive 
either twice-daily intravenous infusions of 600 mg of 
pentoxifylline or placebo in a carrier of 500 ml normal 
saline (total daily dose of pentoxifylline 1200mg) 
given over 4-6h. Infusions were administered in a 
peripheral arm vein; infusion rates were controlled by 
a pump system or drip counter. The infusion rate was 
reduced if the patient experienced side effects uch as 
nausea or vomiting. If fluid overload occurred, the 
volume of vehicle could be reduced (to 250 ml). As an 
alternative to normal saline another vehicle (5% 
dextrose or dextrose/saline) was accepted. Patients 
weighing less than 50kg received only 300mg of 
pentoxifylline or placebo per infusion. Treatment was 
continued for a maximum of 21 days. 
Treatment was discontinued if the patient 
required emergency surgery, failed to show a benefit 
in the relief of rest pain after 7 days or developed a 
serious adverse reaction. 
Endpoints 
The results of pain assessment (pre-infusion pain, pain 
relief, sleep disturbances) were used as primary 
endpoints. Secondary endpoints were the walking 
capacity and an assessment of global clinical impres- 
sion by the physician and the patient at the final 
visit. 
Methodology 
Angiography 
Angiograms were reviewed by an independent radi- 
ologist and scored using the method of Bollinger et 
ai.31 An independent surgical consultant reviewed the 
angiograms and assessed the patient's uitability for 
surgery. 
Haemodynamic measurements 
Distal per fusion pressures were measured as either toe 
pressure, using strain gauge plethysmography (for 
diabetic patients), or as ankle pressures (posterior 
tibial and dorsalis pedis artery) assessed by Doppler 
sonography (for non-diabetic patients). Brachial sys- 
tolic pressures were also recorded, and ankle/arm 
pressure ratios calculated using the higher pressure 
value of the two ankle arteries. 
Pain assessments and analgesic onsumption 
Pain was assessed before the morning infusion (with 
the patient in a supine position, legs not hanging over 
the side of the bed), 3 h after the start of the morning 
infusion and at the end of the infusion. No analgesics 
were given within 4 h prior to the start of the morning 
infusion unless the patient demanded pain relief. 
Three different types of pain indicators were 
studied: pain intensity, sleep disturbance due to pain 
and pain relief during the infusion. Pain intensity was 
assessed using a 4-point score varying from no pain 
(1) to severe pain (4), and a self-report 100 mm visual 
analogue (VA) scale varying from no pain (0 mm) to 
maximum pain (100 mm). Both measures of pain were 
used in an attempt to objectively assess pain intensity 
and to avoid investigator bias. The extent of sleep 
disturbance due to pain was assessed using a 5-point 
questionnaire varying from excellent, i.e. asleep all 
night (1), to poor, i.e. awake most of the night with 
pain (5). Infusion-related pain relief was assessed 
using a 5-point questionnaire varying from no pain 
relief (1) to complete pain relief (5), and a comparison 
of the pain intensity scores before and immediately 
after the end of infusion. In addition, the Burford Pain 
Thermometer, a device for simultaneous measurement 
of pain intensity and analgesic consumption, was used 
to assess the relationship between pain and analgesic 
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consumption. The pain assessment of each patient was 
performed by the same observer each day. 
Walking capacity 
The walking capacity was regarded as a qualitative 
(not quantitative) secondary endpoint. It was of 
interest o see whether short-term infusion treatment 
with pentoxifylline influenced the patients' general 
mobility. Under these conditions it was considered 
appropriate to use three methods to assess the 
walking capacity. Patients completed either a formal 
treadmill test, performed at 3 .2km/h  on a 0% gra- 
dient, or a metronome-control led walking test, per- 
formed at 60 steps/min.  Both the pain-free and 
absolute (maximum) claudication distances were 
recorded where possible. Anecdotal assessments of 
walking ability were made for the remaining 
patients. 
Global clinical impression 
Both patients and physicians gave their subjective 
assessment of the condition at the end of the study 
relative to baseline ( improved/unchanged/  
impaired). 
Sample size and statistical analysis 
The planned sample size was 120 evaluable patients 
per treatment group based on an expected response 
rate of 50% on pentoxifylline compared with 30% on 
placebo (alpha -- 0.05, beta = 0.20). With the exception 
of centre 22, randomisation was stratified by centre 
with a block size of 10. A variable block size was used 
for centre 22. 
All statistical analyses were performed using SAS 
PC(version 6.04). Chi-squared tests, with 95% con- 
fidence intervals, were used for comparing treatment 
effects on the change in preinfusion pain between 
baseline and the final visit. Within each treatment 
group, differences between the VA scale at baseline 
and final visit were compared using Wilcoxon's 
matched-pairs signed rank test. Treatment differences 
in the change in VA scale were compared using 
Wilcoxon's rank sum test. Laboratory data were 
analysed descriptively. For all efficacy analyses, the 
level of significance was 0.05. 
Resu l ts  
A total of 314 patients were enrolled in the study: 157 
patients were randomised to each treatment. Demo- 
graphic and background characteristics are sum-  
Table 1. Demographic and background data 
Pentoxifylline Placebo 
Parameter (n = 157) (n = 157) 
Sex M:F (n) 82:74 79:77 
Age (years, R + S.D,) 72.4 +_ 8.6 73.9 + 8.2 
Weight (kg, R _+ S.D.) 67.7 + 14.1 66.6 + 13.4 
Duration (months): 
Intermittent claudication (IQR a) 24 (7-64) 24.5 (7-57) 
Rest pain (IQR a) 3 (1-6) 3 (1-6) 
Prevalence ofrisk factors (%) 
Smoking history 61 58 
Hypertension 40 29 
Diabetes 33 25 
Treatment ofcardiovascular disease (%) 47 50 
Patients with previous vascular surgery (%) 38 36 
Blood pressure (mmHg) 
Systolic (R + S.D.) 151 _+ 25 152 + 25 
Diastolic (~ + S.D.) 83 + 12 82 + 11 
ABI d (R -+ S.D. b) 0.32 + 0.27 0.31 _+ 0.31 
Segment affected (n) c 
1-segment disease 
Iliac 2 3 
Femoro-pophteal 27 27 
Distal 7 7 
2-segment disease 
Iliac /femoro-popliteal 8 11 
Femoro-popliteal/distal 70 67 
3-segment disease 10 9 
Fontaine stage 
III 83 73 
IV 72 80 
Missing data 2 4 
a IQR, Interquartile range 
b Assessed in n = 141/141 patients 
c Based on Bollinger scores 31 of angiograms ofthe worst affected 
leg 
a ABI, Ankle brachial index pressure 
marised in Table 1; 149 patients on pentoxifylline and 
139 patients on placebo presented with a history of 
intermittent claudication. A history of hypertension 
was more common in the pentoxifylline group 
(p=0.03). However, the blood pressure values at 
baseline were similar. Otherwise there were no differ- 
ences between the two groups. The majority of 
patients had 2- or 3-segmental disease involving the 
femoro-popliteal segment, with most of the significant 
disease being occlusive in nature. Approximately one- 
third of the patients had previously undergone vas- 
cular surger3~ with amputat ion in about 10% of 
patients. Overall, both groups were comparable as 
regards demographic data, prevalence of risk factors 
and anatomical distribution of stenoses and occlusions 
within the lower extremity vascular tree, and repre- 
sentative of a general populat ion suffering from CLI. 
Most patients in each group reported rest pain 
and pain-related sleep disturbance at baseline. A few 
patients reported no pain at the time when baseline 
Eur J Vasc Endovasc Surg Vol 9, May 1995 
430 Intravenous Pentoxifylline for Limb Ischaemia 
rest pain was assessed (pentoxifylline n = 13, placebo 
n = 18); this finding was not unexpected because 
ischaemic rest pain varies in intensity and patients 
were receiving analgesia in hospital. Overall, the 
distribution of pain intensity was similar in each 
Table 2. Baseline pain assessments 
Number (%) of patients 
Pentoxifylline Placebo 
Parameter (n = 157) (n = 157) 
Pain intensity 
Pain score a 
None 13 (8) 18 (12) 
Slight 58 (37) 52 (33) 
Moderate 65 (42) 66 (42) 
Severe 20 (13) 20 (13) 
VA score (mm) b
Median (IQC c) 40 (25-60) 40 (25-60) 
Sleep disturbance a 
Asleep all night 17 (11) 18 (12) 
Undisturbed (no pain) 18 (12) 22 (14) 
Good (awake once) 41 (26) 24 (15) 
Fair (awake 2-3 times) 56 (36) 61 (39) 
Poor (awake most of night) 24 (15) 31 (20) 
a Data missing for one patient in each group 
b Data missing for two patients in the pentoxifylline group and one 
patient in the placebo group 
c IQR, Interquartile range 
group (Table 2). The walking capacity of the two 
groups at baseline was also similar, as shown by the 
absolute claudication distance of patients who under- 
went treadmill testing [pentoxifylline: 77m [inter- 
quartile range (IQR 39-135)], placebo: 58m (IQR 
31-100)]. Approximately two-thirds of patients were 
receiving analgesia in both treatment groups (Table 
3). 
A total of 74 patients on pentoxifylline and 76 
patients on placebo completed the 21-day study; 18 
patients on pentoxifylline and 19 patients on placebo 
were withdrawn before the end of the first week of 
treatment (day 7). A further 50 (15) pentoxifylline 
patients and 48 (14) placebo patients discontinued the 
treatment prematurely before study day 14 (21). The 
reasons for withdrawal are summarized in Table 4. 
The median duration of treatment was similar for both 
groups: 18 days for pentoxifylline and 19 days for 
placebo. 
Efficacy 
Pain assessment (intention-to-treat population) 
Both the pain scores and VA scales showed a statisti- 
catty significant reduction in the intensity of preinfu- 
sion pain in favour of pentoxifylline at the final visit 
(Table 5). Using the pain score system, pain relief was 
reported by 90 patients in the pentoxifylline group 
(58%; 95% C.I. 50-66%). In the placebo group the 
corresponding number was 66 patients (42%; 95% C.I. 
34-49%). The difference in proportion of pain relieved 
was statistically significant in favour of pentoxifylline 
(p = 0.007). These results were confirmed by a strict 
"per protocol" analysis (p = 0.05). Patients on pentox- 
ifylline and placebo showed a median decrease of 22 
and 6 mm respectively on the VA scale (p < 0.001). The 
results of both pain assessment systems correlated 
(r = 0.88). 
No difference was found between the two treat- 
ment groups in terms of pain relief during the course 
of the infusion, indicating the lack of an acute 
analgesic effect of pentoxifylline. Sixty-six patients 
(43%) in the pentoxifylline group reported an increase 
in pain relief during infusion at the end of study 
compared to 58 patients (37%) in the placebo group 
(p--0.33; Table 5). This result was supported by a 
comparison of the pain intensity scores assessed 
before, and directly after, the end of the morning 
infusion on study days 1, 7, 14 and 21. No statistically 
significant difference between the treatment groups 
was found on each of these days. The significant 
reduction in preinfusion pain intensity with pentox- 
ifylline was also associated with a significant reduc- 
tion in pain-related sleep disturbances; 101 (65%) 
patients on pentoxifylline and 75 (48%) patients on 
placebo showed a reduction in pain-related sleep 
disturbance at the final visit (p = 0.003; Table 5). 
Pain assessment in patients with peripheral pressures 
<_ 60mmHg 
In this study severe ischaemia was defined according 
to the criteria described by Bell et al. 29 The European 
Consensus Document on Critical Limb Ischaemia was 
published more recently and included haemodynamic 
parameters to define CLI. 6 A total of 201 (out of 314) 
patients complied with the European Consensus 
definition and showed peripheral pressures 
--- 60 mm Hg (higher value of dors. ped. and post. tib. 
artery pressure). 
As shown in Table 6, 28% (pentoxifylline) vs. 15% 
(placebo) of these patients howed an improvement of 
___ 2 points in the pain-intensity score system 
(p = 0.026). Using the VA scale pentoxifylline-treated 
patients showed a median improvement of 20 mm as 
compared to 5mm under placebo (p=0.007). Both 
results are comparable to those for the overall inten- 
tion-to-treat population. The analgesic consumption 
was reduced in responders of both groups; however, a 
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Table 3. Strongest analgesic taken at baseline and on the last study day 
Number (%) of patients 
Placebo 
Analgesic Baseline 
Pentoxifylline 
Last study day Baseline Last study day 
Single analgesics 18 (11) 12 (8) 33 (21) 17 (11) 
Combination 55 (35) 26 (17) 49 (31) 33 (21) 
Minor opiate 5 (3) 1 (1) 5 (3) 3 (2) 
Major opiate 23 (15) 21 (13) 19 (12) 22 (14) 
Total 101 (64) 60 (38) 106 (68) 75 (48) 
Table 4. Reasons for withdrawal before day 21 (according to 
investigator) 
Number (%) of patients 
Pentoxifylline Placebo 
(n = 157) (n = 157) 
Total withdrawals 83 (53) 81 (52) 
Patient request 22 14 
Deterioration in clinical condition 18 20 
Chemical sympathectomy 5 0 
Surgery / amputation 14 26 
Adverse vent/other illness 19 20 
Other 5 1 
Completed study 74 (47) 76 (48) 
higher number of pentoxifylline than placebo patients 
discontinued analgesics or switched to a milder 
analgesia regimen (Table 3). Additionall)~ Burford 
pain scores were similar within each treatment, 
indicating that the intensity of pain requiring analge- 
sia experienced by patients in each group was similar 
(Table 5). 
Retrospective, exploratory subgroup analyses 
were performed to investigate the effect of prognostic 
factors on treatment response, particularly for diabetes 
and/or  the patient's eligibility for surgery. In the 
intention-to-treat population, diabetes was present in 
52 patients on pentoxifylline and 39 on placebo. At the 
end of the stud3~ there was no apparent difference in 
the reduction of preinfusion pain scores with pentox- 
ifylline between diabetic and non-diabetic patients. 
For diabetic patients, pain scores were reduced in 58% 
of patients on pentoxifylline compared with 33% on 
placebo. For non-diabetics, 58% of patients on pentox- 
ifylline compared with 45% on placebo showed lower 
pain scores. These results were in agreement with the 
overall response rates in the intention-to-treat 
population. 
The pain response in patients who were eligible 
for vascular reconstruction (pentoxifylline: n = 100; 
placebo: n = 99) was tested after 1 week of treatment. 
Reduction of preinfusion pain scores was observed in 
66% of patients on pentoxifylline and 47% on placebo 
at the end of the study. Although response rates were 
slightly lower in patients ineligible for surgery (reduc- 
tion in pain scores in 43% of patients on pentoxifylline 
and 33% on placebo), the trend for each cohort was in 
the same direction and suggested that there were no 
major differences in treatment outcome between the 
groups. 
Both patients' and physicians' subjective global 
assessments of clinical outcome reflected differences 
in response rates observed between the two groups, 
and favoured pentoxifylline. Ninety-three (61%) 
patients on pentoxifylline compared with 67 (44%) 
patients on placebo considered that their condition 
had improved at their final assessment (p= 0.012). On 
the basis of the physicians' assessments, 86 (56%) 
patients on pentoxifylline and 53 (34%) on placebo 
were considered to have improved at their final 
assessment (p < 0.0001). The correlation between the 
two assessments was good (r = 0.84). Furthermore, a 
positive outcome in rest pain was associated with a 
positive outcome in the patients' global assessment. 
Walking capacity 
The walking ability of patients at final visit compared 
to baseline showed some qualitative improvement, 
with a trend in favour of pentoxifylline (p = 0.09). In 
the treadmill-tested subgroup there were no statisti- 
caUy significant differences between the pentoxifylline 
and placebo groups, in either the pain-free or absolute 
claudication distances, at the final visit. 
Safety and tolerability 
Adverse events were reported by 92 (59%) patients 
treated with pentoxifylline and 74 (47%) treated with 
placebo. The higher incidence of adverse vents with 
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Table 5. Change in pain assessments between final visit and baseline (intention-to-treat analysis) 
Number of patients 
Pentoxifylline Placebo 
Treatment comparison 
p-value 
Pre-infusion pain intensity score 
Decrease by -> 1 point 90 (58%) 66 (42%) 
No change/increase 66 90 0.007 
Decrease by ~ 2 points 40 (26%) 26 (17%) 
Decrease < 2 points/increase 116 130 0.052 
Visual analogue scale ~ 
Median (IQR c) -22 (-42-0) -6 (-30-5) < 0.001 
Sleep disturbance 
Decrease 101 (65%) 75 (48%) 
No change/increase 55 81 0.003 
Pain relief during infusion 
Decrease 66 (43%) 58 (37%) 
No change/increase 89 98 0.33 
Burford pain score b
Median (IQR c) 5 (3.5-6) 5 (3.~6.5) 
" Results are given in millimetres 
b Results are note readings on the Burford scale 
c IQR, Interquartile range 
Data not recorded for one patient in each group for pain score and sleep disturbance scores, and for two patients on pentoxifylline and one 
patient on placebo for visual analogue and pain relief scores. 
Table 6. Change in pain assessment at final visit in patients with 
peripheral pressures at baseline a 60 mmHg 
Number (%) of patients 
Pentoxifylline 
(n = 100) 
Pain score (no. of patients) 
Decrease by 3 points 4 (4%) 
Decrease by ~ 2 points 28 (28%) 
Increase by ~ 2 points 3 (3%) 
Increase by 3 points 1 (1%) 
underlying peripheral vascular disease necessitated 
invasive intervention in 36 patients, 17 on pentoxifyl- 
line and 19 on placebo. The overall mortal ity rate was 
Placebo 2.6% (eight patients, four patients in each treatment 
(n = 101) ~- group). 
There were no clinically significant changes in 
0 laboratory safety variables, chest X-ra N ECG or 
15 (15%) physical examination findings with either treatment. 
4 (4%) 
0 
Visual analogue scale (mm) 
Baseline, median (IQR a) 40 (26-60) 39 (21-60) 
Final visit, median (IQR a) 11 (0-33) 27 (4-49) 
Difference (IQR a) -20 (-43-0) -5 (-27-4) 
aIQR, Interquartile range 
"~ntoxifglline was largely accounted for by gastro- 
intesunal symptoms (pentoxifylline: 59 cases, placebo: 
18 cases; p < 0.0001). There was no evidence of local 
irritation: only one patient on pentoxifylline and two 
patients on placebo had evidence of inf lammation at 
the injection site. 
Serious events were experienced by 29 patients on 
pentoxifylline and 38 on placebo. Vascular events 
were the main cause of morbidity and mortality. There 
were four cerebrovascular events with pentoxifylline, 
one of the patients having discontinued treatment 2
weeks prior to the event; there were no reports with 
placebo. Cardiovascular events were seen in four cases 
on pentoxifylline and 13 on placebo. Worsening of the 
Discussion 
There is a clear need for effective conservative 
management  of CLI, both for patients ineligible for 
vascular reconstruction, in whom amputat ion is the 
only alternative, and for patients eligible for recon- 
struction while being prepared for intervention. 
Results of this study have confirmed earlier 
findings 2z-2s and justify the use of intravenous pentox- 
ifylline therapy for the acute management  of CLI. Both 
intention-to-treat nd protocol analyses have shown 
that treatment with pentoxifylline significantly allevi- 
ated the main symptoms of CLI, namely rest pain and 
pain-related sleep disturbances. The possibility that 
these effects were due to an analgesic effect of 
pentoxifylline, or to an increase in analgesic onsump- 
tion, was excluded. Results relating to rest pain and 
sleep disturbances were supported by the outcomes of 
global assessments made by the patient and the 
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physician. As rest pain and sleep-related disturbances 
are the dominant symptoms in CLI patients these 
global assessments might be used as crude means of 
evaluating treatment effects on quality of life. 
The assessment of pain intensity is a subjective 
judgement made by the patient and is therefore 
intrinsically variable; the patient's judgement may 
also be influenced by the trial staff and other factors. 
In order to minimize bias, the study included a dual 
pain assessment system employing a score system and 
a visual analogue (VA) scale. Furthermore, both tests 
were performed by the same staff member at the same 
time of the day (0800h). The pain intensity score shows 
an unexpectedly high placebo effect of about 40% even 
under these conditions. The reason for this may be 
that the patients were asked a biased question which 
caused them to underestimate their pain by at least 1 
scorepoint. A further possible explanation lies in the 
interpretation of the data, and the definition of the 
degree of pain alleviation which is regarded as being 
clinically relevant. It is almost impossible to give a 
general definition of this for all CLI patients, but it is 
generally agreed that minimal changes in pain cannot 
be regarded as being clinically relevant. 
There is no scientific justification to view a pain 
reduction of 1 scorepoint as being minimal and 
irrelevant. If, however, this is assumed and only 
improvements of ~ 2 points are considered, the 
response rates for pentoxifylline and placebo treat- 
ment are 26% and 17% respectively. The placebo effect 
thus lies in the expected range and corresponds to 
results of prostaglandin E 1 (PGE1) studies.B2(Prosta - 
glandin E 1 is licensed in several European countries 
for the treatment of CLI). From this discussion it may 
be concluded that the results of the assessment of pain 
intensity with the VA scale can be regarded as being 
more valid than the results of the pain score system. 
Hence VA scales should be used rather than score 
systems in future trials on CLI patients. 
The definition of CLI has been the subject of 
considerable discussion. Whereas in this study the Bell 
criteria were applied 29 the European Working Group 
on Critical Limb Ischaemia 6 has proposed a definition 
employing both clinical and haemodynamic parame- 
ters. If a pressure cutoff point of 60 mmHg is chosen 32 
201 patients, out of the intention-to-treat population of 
314, comply with both the Bell and the European 
Working Group criteria. As shown in Table 6, the 
results from this subpopulation are similar to those 
from the intention-to-treat population. Using the score 
system, 28% of the pentoxifylline and 15% of the 
placebo patients described a pain decrease of a 2 
points (p=0,026). In the VA scale the absolute 
decreases reached with pentoxifylline and placebo 
amounted to 20 mm and 5 mm respectively (p= 0.007). 
Again, the results from both assessment systems 
showed an acceptable correlation (r= 0.90). It-can thus 
be concluded that the pentoxifylline data remain valid 
regardless of whether the Bell or the European 
Consensus criteria are used for the definition of CLI. 
Demographic and background characteristics 
(Table 1) were comparable in all groups described 
above (intention-to-treat population, subpopulation) 
and were representative for a general elderly popula- 
tion suffering from severe peripheral vascular dis- 
ease. 1'2"5'33-36 Hence results shown in this trial can be 
extrapolated to a general CLI population at large. 
The alleviation of rest pain seen in the pentoxifyl- 
line group was independent of an analgesic effect of 
the drug itself. The most likely explanation for this 
would be an improvement in microcirculatory perfu- 
sion of the end organ, i.e. the skeletal muscle. There is 
sufficient evidence from the literature that pentoxifyl- 
line does improve the intramuscular pO2 in PVD 
patients. 37-39 However, in a large scale multicentre 
clinical trial this is difficult to prove because reliable 
intramuscular pO 2 measurements ot only require the 
instalment of the apparatus in all centres, but also 
demand adequate skill and experience to use it 
appropriately. For several reasons, the assessment of
cutaneous perfusion parameters (tcpO2, Laser-Dop- 
pler, capillary microscopy) is not a true alternative. 
Firstly, sufficient correlation between muscular perfu- 
sion and the perfusion of skin capillaries may only be 
expected if the cutaneous hunt perfusion remains 
constant. Secondl~ Laser-Doppler sonography and 
capillary microscopy are characterised bya high inter- 
and intraindividual variability of the results, which 
qualifies these techniques for the assessment of 
dynamic perfusion changes with acceptable accuracy. 
In the long-term follow-up of a large patient sample, 
however, their use is rather laborious. Finally, an 
important determinant for the methodology to be 
applied in a clinical trial is the number of centres 
involved. With 18 centres cattered throughot{t Europe 
sophisticated techniques, which are extremely helpful 
in single centre trials, need to be avoided, and if 
meaningful results are to be obtained, endpoints must 
aim at clinical variables. 
The overall incidence of adverse events was 
similar for pentoxifylline and placebo and was also 
similar to side effect rates reported in other stud- 
ies. 21-28 However, there were more gastrointestinal 
symptoms with pentoxifylline, as this is well known 
29 from its side effect profile. Taking into account hat 
CLI patients are at risk and severely ill, the risk/ 
benefit ratio for intravenous pentoxifylline appears to 
be positive; thus the use of this drug for the acute 
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management of CLI seems to be justified, as has been 
confirmed in other studies. 4°-42 
The basis for any therapeutic approach to CLI, 
whether conservative therapy, thrombolysis, urgery 
or dilatation, is a risk/benefit assessment for each 
patient. Published literature on the 30-day mortalit)~ 
30-day morbidity and early and late failures in 
reconstructive surgery or PTA 43-55 ethically justifies 
these two procedures. PTA- and surgery-related mor- 
tality have been estimated to be 0.2-1;4% and 1-9% 
respectively; estimates for PTA- and surgery-related 
morbidity are 3-15% and 10-20% respectively. Long- 
term (2 to 4 years) reocclusion rates are similar for 
both procedures and estimates range between 20 and 
40% for the iliac and between 30 and 60% for the 
femoropopliteal segment. 43'49'51-s3'55 However, it has 
to be taken into consideration that the above figures 
represent longitudinal results for a general PVD 
population consisting of intermittent claudicants and 
CLI patients who require PTA or bypass surgery. CLI 
patients often present with an involvement ofall three 
lower extremity vascular segments, an impaired in- 
and outflow tract and hence a limited probability of 
successful surgica! reconstruction. Also 50-80% and 
30-60% of these patients suffer from symptomatic 
coronary heart disease and extracranial carotid artery 
disease respectively; 4"7-1°'56'57 chronic obstructive pul- 
monary disorders and cardiac failure are also common 
in this multirisk elderly population. Consequentl3~ the 
true figures for the 30-day morbidity and mortality 
and data on long-term outcome are considerably 
higher than those cited above. If a major amputation is 
required, hospital mortality may be as high as 30% 
and the percentage of non-lethal complications even 
higher. These figures are reported by Harris and 
Moody 58 and are based on the official British amputa- 
tion statistics; they have also been confirmed by other 
authors. 59-62 Furthermore, the chances for rehabilita- 
tion and social reintegration after above-knee or 
below-knee amputation are as low as a 25% and 
_< 40% 60 and the mean survival time ranges between 3
and 6 years. 61-63 In diabetics the situation is worse. 
They do not only carry a five-fold increased risk of 
PVD progression from intermittent claudication to 
CLI, 6 but also show a 10-fold increased risk of 
amputation if CLI occurs. 
Although long-term outcome was not assessed in 
this stud~ there is evidence that pentoxifylline infu- 
sion therapy followed by oral treatment may show a 
long-term benefit. McCollum and Galvin both showed 
that, in responders, the need for invasive treatment 
could be reduced in the 6-12 months following acute 
pentoxifylline infusion. 25'26 Trfibestein et al. 27 com- 
pared pentoxifylline to PGE1 treatment and showed 
that pentoxifylline was efficacious, even though only 
half of the recommended dose was used for the acute 
treatment phase, and patients were not switched to 
oral treatment during the one year follow-up. Taking 
all available pentoxifylline data together (this 
stud3~ zz-2s) and comparing them with published 
results on PGE1, PGIz and prostacyclin ana- 
logues, 27'32'64-71 it can be shown that the magnitude of 
response in terms of acute relief of rest pain, healing 
rates of ischaemic lesions and results from long-term 
follow-up is similar. 
In conclusion, the infusion of 600 mg pentoxifyl- 
line twice daily for a period of up to 21 days gave pain 
relief in the acute management of CLI. Treatment 
outcome was not influenced by the presence of 
diabetes, the eligibility for surgery or by extremely 
impaired peripheral haemodynamics. 
Acknowledgement 
This study was funded by Hoechst AG, Werk Kalle-Albert, D-65174, 
Weisbaden, Germany and a grant from the Swedish Medical 
Research Council, 00759. 
References 
1 DORMANDY Jr MAHIR M/ASCADY Get al. Fate of the patient with 
chronic leg ischaemia. J Cardiovasc Surg 1989; 30(Suppl 1): 
50-57. 
2 JELNES R / GAARDSTING O, HOUGAARD JENSEN HK, BAEKGAARD N, 
TOENNESEN KI-I, SCHROEDER T: Fate in intermittent c.laudication: 
outcome and risk factors. Br Med J 1986; 293: 1137-1140. 
3 CRONENWETT JL, WARNER KG, ZELENOCK GB, et al. Intermittent 
claudication: current results of nonoperative management. Arch 
Surg 1984; 119: 430-436. 
4 NASCHITZ JE, AMBROSIO DA, CHANG JB. Intermittent claudication: 
Predictors and outcome. Angiology 1988; 39: 16-22. 
5 ROSENBLOOM MS, FLANIGAN DE SCHULER JJ et al. Risk factors 
affecting .the natural history of intermittent daudication. Arch 
Surg 1988; 123: 867-870. 
6 EUROPEAN WORKING GROUP ON CRITICAL Lm ISCHAEMIA. Second 
European Consensus Document on Chronic Critical Leg Ischae- 
rnia. Circulation 1991; 84(Suppl IV): IV1-IV26. 
7 JANSON R~ NEUHAUS G, THELEN M. Extrakranielle arterieUe 
Verschlu[3krankheit bei gefa[3chirurgischen Patienten mit per- 
ipheren Durchblutungsst6rungen. Fortschr R6ntgenstr 1980; 133: 
484-493. 
8 HERTZER NR, BEVEN EG, YOUNC JR et al. Coronary artery disease 
in peripheral vascular patients, h dassification of 1000 coronary 
angiograms and results of surgical management. Ann Surg 1984; 
4: 223-233. 
9 SIEBEN U / MOLLER-BOHL U, BERGER B, MORL H, SCHULER G, DIEHM 
C. Arterielle Verschluf3krankheit und koronare Herzkrankheit - 
gemeinsame Pravalenz und Risikofaktoren. VASA 1987; 
20(Suppl): 264-265. 
STELNKE W, AL-DEEB S, HENNERICI M. Prfivalenz extrakranieller 
Gef/i[3prozesse und Risikoprofil bei Patienten mit peripherer und 
koronarer Angiopathie. VASA 1987; 16: 283-290. 
COFFMANN JD. Intermittent claudication: ot so benign. Am Heart 
J 198@ November: 427--428. 
10 
11 
Eur J Vasc Endovasc Surg Vol 9, May 1995 
The European Study Group 435 
12 VERSTRAETE M, ed. Methods in Angiology. A physical-technical 
introduction written for clinicians by physicians. The Hague/ 
Boston/London: Martinus Nijhoff, 1980. 
13 KAPPERT A, ed. Lehrbuch und Atlas der Angiologie. Bern/Stuttgart/ 
Toronto: Hans Huber, 1990. 
14 Lows GDO. Pathophysiology of critical limb ischaemia, in 
Dormandy JA, STOCK G, eds. Critical eg ischaemia: its pathophysiol- 
ogy and management. Berlin/Heidelberg: Springer, 1990: 17-38. 
15 NASH GB, THOMAS PRS, DORMANDY JA. Abnormal flow proper- 
ties of which blood cells in patients with severe ischaemia of the 
leg. Br Med J 1988; 296: 1699-1701. 
16 PORTER JM, CUTLER BS, LEE BY. Pentoxifyliine fficacy in the 
treatment of intermittent claudication: Multicenter controlled 
double-blind trial with objective assessment. Am Heart ] 1982; 
104: 66-72. 
17 GILLINGS D, KOCH G, REICH T, STAGER WJ. Another look at the 
pentoxifylline fficacy data for intermittent claudication. J Clin 
Pharmacol 1987; 27: 601-609. 
18 ROSSNER M, MOLLER R. On the assessment of the efficacy of 
pentoxifylline (Trental). J Med 1987; 18: 1-15. 
19 WARD A, CLISSOLD SP. Pentoxifylline. A review of its pharmaco- 
dynamic and pharmacokinetic properties, and its therapeutic 
efficacy. Drugs 1987; 34: 50-97. 
20 LINDG~RDE R, JELNES R, BJORKMAN H, et al. Of the Scandinavian 
Study Group. Conservative drug treatment in patients with 
moderately severe chronic occlusive peripheral arterial disease. 
Circulation 1989; 80: 1549-1556. 
21 THOMSON GJL, THOMSON S, TODD AS, VOHRA RK, CARR MH, 
WAI~KER MG. Combined intravenous and oral pentoxifylline in 
the treatment of peripheral vascular disease. A clinical trial. Int 
Angiol 1990; 9: 266-270. 
22 ANGELKORT B, SPf~RK P~ HABBABA A, MAHDER M. Blood flow 
properties and walking performance in chronic arterial ocdusive 
disease. Angiology 1985; 36: 285-292. 
23 ANGELIDES NS. Continuous infusion treatment with pentoxifyl- 
line in patients with severe peripheral vascular occlusive 
disease. Angiology 1986; 37: 555-564. 
24 FARRAJOTA A, SOUSA LUZ E, ALBINO P~ ME1RELES M. Isqu6mia 
cr6nica dos membros inferiores grau III/IV de Leriche-Fontaine 
em doentes diab6ticos. Ensaio coma Pentoxifilina. Jornal das 
Ci~ncias Mddicas 1989;CLIII. 
25 GALVIN KT, GORST KL, PRIMROSE JN, KESTER RC. Intravenous 
oxpentifylline in critical imb ischaemia. Br J Clin Pract 1989;43: 
169-172. 
26 McCoLLUM P% KENT P~ O'DRIsCOLL K, et aI. Intravenous 
pentoxifylline in the treatment of rest pain: a preliminary report. 
Ann Vasc Surg 1989; 3: 220-223. 
27 TROBESTEIN G, VON BARY S, BREDDIN K, et al. Intravenous 
prostaglandin E1 versus pentoxifylline therapy in chronic arte- 
rial occlusive disease - a controlled randomised multicenter 
study. VASA 1989; (Suppl 28): 4449. 
28 ZAHAVI J, WALDEN R r BASS A, et al. Efficacy of short term 
intravenous pentoxifylline in the management of patients with 
advanced peripheral arterial occlusive disease. Prog Angiol 1991; 
211-216. 
29 BELL PRF, CHARLESWORTH D, DEPALMA RG, et aI. The definition of 
critical ischaemia of a limb. Br ] Surg 1982; 69(Suppl 1): $2. 
30 FONTAINE Rr KIM MI KIENY R. Die chirurgische Behandlung der 
peripheren Durchblutungsst6rungen. Helvetica Chirurgica Acta 
1954; 5/6: 499-533. 
31/BoLLINGER A, BREDD1N K, HESS H, et aL Semiquantitative 
assessment of lower limb atherosclerosis from routine angio- 
graphic images. Atherosclerosis 1981; 38: 339-346. 
32 DIEHM C, HUBScH-MOLLER C, STAMMLER F. Intraven6se Prosta- 
glandin E1-Therapie bei Patienten mit peripherer arterielier 
Verschlu~krankheit (AVK) im Stadium II I-  eine doppelblinde, 
plazebo-kontrollierte S udie. In: HEIDRICH H, BOHME H, ROGATTI 
W, eds. Prostagtandin E1-Wirkungen und therapeutische Wirksam- 
keit. Berlin/Heidelberg/New York: Springer, 1988: 133-143. 
33 WIDMER LK, GREENSHER A, KANNEL WB. Occlusions of peripheral 
arteries: A study of 6400 working subjects. Circulation 1964; XXX: 
836--842. 
34 KANNEL WB, SKINNER JJ, SCHWARTZ MJ, SHURTLEFF D. Intermittent 
daudication. Incidence in the Framingham Study. Circulation 
1970; XLI: 875-883. 
35 PEABODY CNt KANNEL WB, MCNAMARA PM. Intermittent claudi- 
cation: Surgical significance. Arch Surg 1974; 109: 693-697. 
36 C~QUI MH, FRONEK A, BARRETT-CONNOR E et al. The prevalence 
of peripheral arterial disease in a defined population. Circulation 
1985; 71: 510-515. 
37 EHRLY AM, SCHROEDER W, DANNHOF S. The effect of pentoxifyl- 
line on the oxygen pressure of ischaemic muscle tissue in 
patients with chronic arterial disease. IRCS Med Sci 1977; 5 
411. 
38 EHRLY AM. Effects of orally administered pentoxifylline on 
muscular oxygen pressure in patients with intermittent claudica- 
tion. IRCS Med Sci 1982; 10: 401-402. 
39 EHRLY AM, SAEGER-LORENZ K. Influence of pentoxifylline on 
muscle tissue oxygenation tension (pOz) of patients with 
intermittent claudication before and after ergometer exercise. 
Angiology 1987; 38: 93-100. 
40 ANGELKORT B, BAUERDICK H: Gum Verhalten des Herzrhythmus 
bei digitalisierten Patienten mit zusatzlicher Pentoxifyllin-Medi- 
kation. Therapiewoche 1982; 32: 5369-5371. 
41 INGERSLEV j, MOLrRITZEN G, STENBJERG S. Pentoxifylline does not 
interfere with stable coumarin anticoagulant therapy: a clinical 
study. Pharmatherapeutica 1986; 4: 595--600. 
42 SOLERTE SB, FIORAVANTI M, BOZZETTI A. Pentoxifyliine, albumin 
excretion rate and proteinuria in type I and type II diabetic 
patients with microproteinuria. Results of a short term rando- 
mised study. Acta Diabeteol Lat 1986;23: 171-176. 
43 GArnER H, GRONTZIG A, ZEITLER E. Late results after percutaneous 
transluminal angioplasty of iliac and femoropopliteal obstruc- 
tive lesions - -  A cooperative stud~ In DOTTER C% GRONTZIG A, 
SCHOOP Wr ZEITLER E, eds. Percutaneous Transluminal Angioplasty. 
Berlin/Heidelberg: Springer, 1983: 215-218. 
44 RUSH DS, GEWERTZ BL, Lu CT, BALL DG, ZARINS CK. Limb 
salvage in poor-risk patients using transluminal angioplasty. 
Arch Surg 1983; 118: 1209-1212. 
45 SCHNEIDER E, GRONTZIG A, BOLLINGER A. Percutaneous trans- 
luminal angioplasty for limb salvage - -  Progress in therapy for 
severe leg ischemia with rest pain and gangrene. In: DOTTER C% 
GRONTZIG A, SCHOOP W, ZEITLER E I eds. Percutaneous Transluminal 
Angioplasty. Berlin/Heidelberg: Springer, 1983: 222-226. 
46 GALLINO A, MAHLER F, PROBST P, NACHBUR B. Percutaneous 
transluminal angioplasty of the arteries of the lower limbs: a 5 
year follow-up. Circulation 1984; 70: 619-623. 
47 JoNEs BA, MAGGISANO R, ROBB C, SAIBIL EA, WFFCHELL SJ, 
HARIKISON AW. Transluminal angioplasty: Results in high-risk 
patients with advanced peripheral vascular disease. Can ] Surg 
1985; 28: 150-152. 
48 FLETCHER JP, LITTLE JM, FERMANIS GG, SIMMONS K. Percutaneous 
transluminal ngioplasty for severe lower extremity ischaemia. 
Aust NZJ Surg 1986; 56: 121-125. 
49 HARPaS PL, CAMPBELL H. Femoro-distal bypass for critical 
ischaemia: is the use of prosthetic grafts justified? Ann Vasc Surg 
1986; 1: 66-72. 
50 JOHNSTON I~A/', RAE M, HOGG-JOHNSTON SA, et al. 5:year esults of 
a prospective study of percutaneous transluminal angioplasty. 
Ann Surg 1987; 206: 403-413. 
51 CAPEK P, McLEAN GK, BERKOWITZ HD. Femoropopliteal ngio- 
plasty. Factors influencing long-term success. Circulation 1991; 
83(Suppl I):I-70-I-80. 
52 JOHNSTON K'VvV. Aortoiliac disease treatment. Circulation 1991; 
83(Suppl I):I-61-I-62. 
53 MARTIN EC. Transcatheter therapy in peripheral and non- 
coronary vascular disease. Circulation 1991; 83(Suppl I):I-l-I-5. 
54 TEGTMEYER CJ, HARTWELL GD, SELBY JB, ROBERTSON R, KRON IL, 
TRIBBLE CG. Results and complications of angioplasty in aortoi- 
liac disease. Circulation 1991; 83(Suppl I): 1-53-I-60. 
55 JOERGENSEN B, SKOVGARD N, NOERGARD J, KARLE A, HOLSTEIN P. 
Percutaneous transluminal ngioplasty in 226 iliac artery steno- 
ses: Role of the superficial femoral artery for clinical success. 
VASA 1992;21: 382-386. 
Eur J Vasc Endovasc Surg Vol 9, May 1995 
436 Intravenous Pentoxifylline for Limb Ischaemia 
56 TURNIPSEED WD, BERKOFF HA, BELZER FO. Postoperative stroke in 
cardiac and peripheral vascular disease. Ann Surg 1980;192: 
365-368. 
57 DIENER HC, SEBOLDT H, DICHGANS J, ANDRIS M, SPRINGER G, 
BAIKER R. Stenosen und Verschliisse der extrakraniellen Arterien. 
Feldstudie an unausgewahlten Personen und bei Patienten mit 
Claudicatio intermittens. Dtsch med Wschr. 1983; 108: 496-500. 
58 HARRIS P, MOODY P. Amputations, in Dormandy JA, Stock G eds. 
Critical leg ischaemia --Its pathophysiology and management. Ber- 
lin/Heidelberg: Springer, 1990: 87-98. 
59 HARRIS PL, READ F, EARDLEY A, CHARLESWORTH D, WAKEFIELD J, 
SELLWOOD RA. The fate of elderly amputees. Br J Surg 1974; 61: 
665-668. 
60 DORMANDY J, ed. European Consensus Document on Critical Limb 
Ischaemia. Berlin/Heidelberg/New York: Springer, 1989. 
61 GREANT P~ VAN DEN BRANDE P. Amputation in elderly and high- 
risk vascular patients. Ann Vasc Surg 1990; 4: 288-290. 
62 INDERBITZI R, BOTTIKER M, PFLUGER D, NACHBUR B. The fate of 
bilateral lower limb amputees in end-stage vascular disease. Eur 
J Vasc Surg 1992; 6: 321-326. 
63 STEWART CPU, JAIN AS, OGSTON SA. Lower limb amputee 
survival. Prosthetics and Orthotics International 1992; 16: 11-18. 
64 SCHULER JJ, FLANIGAN DP, HOLCROFT JW, URSPRUNG JJ, MOHRLAND 
JS, PYKE J. Efficacy of prostaglandin E 1 in the treatment of lower 
extremity ischemic ulcers secondary to peripheral vascular 
occlusive disease. J Vasc Surg 1984;1 160-170. 
65 TROBESTEIN G, DIEHM C, GRUSS JD, HORSCH S. Prostaglandin E~ in 
chronic arterial disease - a multicenter study. VASA 1987;(Suppl 
17) 39--43. 
66 BALZER K, BECHARA G, BISLER H, et al. Placebo-kontrolfierte, 
doppelblinde Multizenterstudie zur Wirksamkeit von Iloprost 
bei der Behandlung ischamischer Ruheschmerzen von Patienten 
mit peripheren arteriellen Durchblutungsst6rungen. VASA 1987; 
(Suppl 20): 379-381. 
67 BOHME H, BRCdLISAUER M, HARTEL U, BOLLINGER A. Kontrollierte 
Zweizentren-Studie zur Wirksamkeit v0n intraarteriellen Prosta- 
glandin E~-Infusionen bei peripherer arterieller Verschlu~kran- 
kheit im Stadium III und IV. In HEIDRICH H, BOHME H, ROGATTI W 
eds. Prostaglandin - E1-Wirkungen und therapeutische Wirksamkeit. 
Berlin/Heidelberg/New York: Springer, 1988: 118-123. 
68 HEIDRICH H, RANFT J, PETERS A, RUMMEL S. Intraven6se Prostava- 
sin-Therapie bei peripherarteriellen Durchblutungsst6rungen im 
Fontaine-Stadium III und IV. Frfih- und Spatergebnisse einer 
Screening-Studie, In: HEIDRICH H, BOHME H, ROGATrI Weds.  
Prostaglandin - E1-Wirkungen und therapeutische Wirksamkeit. 
Berlin/Heidelberg/New York: Springer, 1988: 112-117. 
69 DIEHM C, ABRI O, BE1TSCH Get  al. Iloprost, ein stabiles 
Prostacyclinderivat, bei arterieller VerschluOkrankheit im Sta- 
dium IV. DMW 1989; 114: 783-788. 
70 NORGREN L, ALWMARK A, /~NGQVIST KA. A stable prostacyclin 
analogue (Iloprost) in the treatment of ischaemic ulcers of the 
lower limb. Eur J Vasc Surg 1990; 4: 463-467. 
71 GUILMOT JL, DIOT E. Treatment of lower limb ischaemia due to 
atherosclerosis in diabetic and nondiabetic patients with Ilo- 
prost, a stable analogue of prostacyclin. Drug Invest 1991; 3: 
351-359. 
Accepted 22 September 1994 
Eur J Vasc Endovasc Surg Vol 9, May 1995 
